San Diego's UC San Diego Moores Cancer Center and Scripps MD Anderson Cancer Center manage significant volumes of prostate cancer patients from San Diego County and across the US-Mexico border region. For San Diego's large Latino and Hispanic population — where prostate cancer mortality rates are disproportionately elevated due to later-stage diagnosis and treatment access barriers — Abiranamo 250mg at dramatically reduced cost versus brand Zytiga makes sustained life-extending therapy genuinely accessible.
Visit unnatipharmax.com | 📱 +91 82650 41513 | 📧 Unnatipharmax@gmail.com
FAQ 1: What is the difference between mCRPC and mHSPC — and does Abiranamo work for both?mHSPC (metastatic hormone-sensitive prostate cancer) refers to metastatic disease that still responds to standard androgen deprivation therapy (ADT) — testosterone can still be suppressed to castrate levels and the cancer responds. mCRPC (metastatic castration-resistant prostate cancer) means the cancer is progressing despite castrate testosterone levels, having developed mechanisms to survive androgen deprivation. Abiraterone is approved and highly effective in both settings. In mHSPC, adding Abiraterone to standard ADT (LATITUDE trial) significantly extends survival versus ADT alone — treating the disease earlier, more aggressively. In mCRPC (both pre- and post-chemotherapy — COU-AA-302 and COU-AA-301 trials), Abiraterone extends overall survival significantly. San Diego's UCSD oncologists use Abiraterone in both settings, with the timing decision based on patient-specific risk factors and disease characteristics. FAQ 2: How does the US-Mexico border context affect prostate cancer care for San Diego patients?San Diego's border context creates unique clinical realities. Many patients are cross-border healthcare seekers — receiving some care in Tijuana (often cheaper) and some in San Diego (for specialist technology or insurance coverage). This dual-care situation creates communication gaps between Mexican and US treating physicians, potential for different diagnostic staging methods, and risk of medication inconsistency. For prostate cancer specifically, some San Diego patients obtain generic Abiraterone from Mexican pharmacies — available there at lower cost than US branded Zytiga. Understanding this pattern, UCSD oncologists ask specifically about medications obtained in Mexico to ensure no duplication or interaction with US prescriptions. Affordable generic Abiranamo from Unnati Pharmax serves this same need — providing quality-assured, WHO-GMP certified supply for San Diego's border population. FAQ 3: What is the role of PSMA PET-CT imaging before starting Abiranamo for prostate cancer?PSMA PET-CT (Prostate-Specific Membrane Antigen Positron Emission Tomography) is now considered the most sensitive imaging modality for detecting prostate cancer metastases, having essentially replaced conventional bone scan and CT in many centres including UCSD Moores. PSMA PET-CT detects metastatic lesions at PSA levels as low as 0.2-0.5 ng/mL — far earlier than conventional imaging. Before starting Abiranamo, PSMA PET-CT accurately characterises the extent and distribution of metastatic disease, distinguishing mHSPC from nmCRPC (non-metastatic CRPC), and identifying PSMA-expressing lesions that predict future eligibility for Lu-177 PSMA radioligand therapy. The staging accuracy of PSMA PET-CT also improves clinical trial eligibility assessment and enables more personalised treatment planning — San Diego's UCSD uses it routinely for all newly diagnosed metastatic prostate cancer patients. FAQ 4: What are the signs that Abiranamo treatment is failing and disease is progressing?Progressive disease on Abiranamo is recognised through several indicators used together rather than any single measurement alone. PSA rise — a confirmed 25%+ increase from nadir (lowest PSA achieved) on at least two consecutive measurements — is a key biochemical marker. Radiological progression — new bone metastases on bone scan or new/enlarging soft tissue lesions on CT/MRI — indicates clear disease progression. Clinical progression — worsening pain at metastatic sites, new neurological symptoms from cord compression, or declining performance status — signals clinical deterioration. The PCWG3 (Prostate Cancer Working Group 3) criteria define progression more precisely and guide clinical trial eligibility. Importantly, a single PSA rise or single new bone scan lesion doesn't always trigger Abiranamo discontinuation — San Diego oncologists assess the full clinical picture and often confirm progression before changing therapy. FAQ 5: Can exercise and lifestyle changes genuinely improve outcomes for San Diego prostate cancer patients on Abiranamo?Growing evidence supports exercise as a genuine co-treatment for prostate cancer — not just quality-of-life improvement. Randomised controlled trials show that structured aerobic and resistance exercise during ADT-based therapy (including Abiraterone): reduces ADT-related muscle loss (sarcopenia) which independently predicts worse cancer outcomes; improves bone density — counteracting ADT's bone-thinning effects; reduces fatigue — the most evidence-based non-pharmacological fatigue intervention; improves cardiovascular fitness reduced by ADT; and may have direct anti-tumour immune effects through exercise-induced cytokine changes. San Diego's favourable climate enables year-round outdoor exercise — a genuine lifestyle advantage for prostate cancer patients. UCSD's MOVE Program (exercise oncology programme) provides supervised exercise specifically designed for men on ADT-based prostate cancer therapy, and San Diego's outdoor culture makes adherence more achievable than in less favourable climates.
